Remission inductive efficacy of the combination of ARB, MRA, and saireito for nephrotic syndrome of membranous nephropathy

Abstract

Angiotensin II receptor blockers (ARBs) effectively reduce urinary protein. An increase in aldosterone after ARB is termed aldosterone breakthrough and mineralocorticoid receptor antagonists (MRAs) are useful against this phenomenon. The Japanese traditional medicine saireito has the potential to reduce proteinuria. MRAs may suppress licorice‐induced pseudoaldosteronism.